
**CREDIT NUMBER 6977-CV
and
First Amendment to CREDIT NUMBER 6837-CV**

Financing Agreement

**(Cabo Verde COVID-19 Emergency Response Project – Third Additional
Financing)**

between

REPUBLIC OF CABO VERDE

and

INTERNATIONAL DEVELOPMENT ASSOCIATION

**CREDIT NUMBER 6977-CV
and
First Amendment to CREDIT NUMBER 6837-CV**

FINANCING AGREEMENT

AGREEMENT dated as of the Signature Date between REPUBLIC OF CABO VERDE (“Recipient”) and INTERNATIONAL DEVELOPMENT ASSOCIATION (“Association”) for the purpose of providing additional financing for activities related to the Original Project (as defined in the Appendix to this Agreement). The Recipient and the Association hereby agree as follows:

ARTICLE I — GENERAL CONDITIONS; DEFINITIONS

- 1.01. The General Conditions (as defined in the Appendix to this Agreement) apply to and form part of this Agreement.
- 1.02. Unless the context requires otherwise, the capitalized terms used in this Agreement have the meanings ascribed to them in the General Conditions or in the Preamble or in the Appendix to this Agreement.

ARTICLE II — FINANCING

- 2.01. The Association agrees to extend to the Recipient a credit, which is deemed as Concessional Financing for purposes of the General Conditions, in the amount of seven million Special Drawing Rights (SDR 7,000,000) (variously, “Credit” and “Financing”), to assist in financing the project described in Schedule 1 to this Agreement (“Project”).
- 2.02. The Recipient may withdraw the proceeds of the Financing in accordance with Section III of Schedule 2 to this Agreement.
- 2.03. The Maximum Commitment Charge is one-half of one percent (1/2 of 1%) per annum on the Unwithdrawn Credit Balance.
- 2.04. The Service Charge is three-fourths of one percent (3/4 of 1%) per annum on the Withdrawn Credit Balance.
- 2.05. The Payment Dates are June 15 and December 15 in each year.
- 2.06. The principal amount of the Credit shall be repaid in accordance with the repayment schedule set forth in Schedule 3 to this Agreement.
- 2.07. The Payment Currency is Dollar.

ARTICLE III — PROJECT

- 3.01. The Recipient declares its commitment to the objective of the Project and the MPA Program. To this end, the Recipient shall carry out the Project in accordance with the provisions of Article V of the General Conditions and Schedule 2 to this Agreement.

ARTICLE IV — EFFECTIVENESS; TERMINATION

- 4.01. The Additional Conditions of Effectiveness consist of the following, namely that the Recipient has updated the ESMF, LMP, SEP, GBV Action Plan, MWMP and Workers GRM, in a manner acceptable to the Association.
- 4.02. The Effectiveness Deadline is the date ninety (90) days after the Signature Date.
- 4.03. For purposes of Section 10.05(b) of the General Conditions, the date on which the obligations of the Recipient under this Agreement (other than those providing for payment obligations) shall terminate is twenty (20) years after the Signature Date.

ARTICLE V — REPRESENTATIVE; ADDRESSES

- 5.01. The Recipient's Representative is the MOF.
- 5.02. For purposes of Section 11.01 of the General Conditions:
- (a) the Recipient's address is:
- Ministry of Finance
Avenida Almilcar Cabral
C.P. 30, Praia
Cabo Verde; and
- (b) the Recipient's Electronic Address is:
- E-mail:

gilson.g.pina@mf.gov.cv; and soeli.d.santos@gov.cv
- 5.03. For purposes of Section 11.01 of the General Conditions:
- (a) the Association's address is:
- International Development Association
1818 H Street, N.W.
Washington, D.C. 20433
United States of America; and

(b) the Association's Electronic Address is:

Telex: Facsimile:
248423 (MCI) +1-202-477-6391

AGREED as of the Signature Date.

REPUBLIC OF CABO VERDE

By

H.E Olavo Avelino Garcia Correia

Authorized Representative

Name: H.E Olavo Avelino Garcia Correia

Title: Minister of finance

Date: 03-jul-2021

INTERNATIONAL DEVELOPMENT ASSOCIATION

By

Nathan M. Belete

Authorized Representative

Name: Nathan M. Belete

Title: Country Director

Date: 02-Jul-2021

SCHEDULE 1

Project Description

The objective of the Project is to prepare and respond to the COVID-19 pandemic in Cabo Verde.

The Project constitutes a part of the MPA Program and consists of the following Parts:

Part 1: Emergency COVID-19 Preparedness, Prevention and Response

- 1.1 Supporting implementation of prevention, detection and response activities in the National COVID-19 Preparedness and Response Plan, including the following:
 - (a) acquisition of COVID-19 diagnostics tests, emergency medical and non-medical supplies such as gloves, surgical masks, respirators, eye protection wear and isolation gowns as well as infection prevention and control materials for health workers and health facilities;
 - (b) rehabilitation and provision of medical equipment and supplies to designated health facilities in the Recipient's islands of *Sal* and *Boa Vista*;
 - (c) strengthening the capacities of laboratories in selected health facilities through provision of critical consumables, reagents, and equipment stock for emergencies and COVID-19 testing;
 - (d) acquisition of medical equipment such as diagnostic and life support equipment and durable medical equipment such as hospital and surgical beds and surgical instruments to support the response, treatment and isolation of infected severe and critical cases; and
 - (e) acquisition of vehicles for emergency operations including for transportation medicines, supplies, biological surveillance samples and blood products.
- 1.2 Supporting Project COVID-19 Vaccine acquisition, planning and distribution, including the following:
 - (a) supporting the development of MHSS's national deployment and vaccination plan and associated budget;
 - (b) developing a regulatory framework and plans to ensure swift importation of the Project COVID-19 Vaccines;

- (c) providing training to health personnel for Project COVID-19 Vaccine roll out;
- (d) supporting the acquisition, storage and distribution of Project COVID-19 Vaccines;
- (e) supporting the acquisition and distribution of ancillary supply kits, COVID-19 vaccination record cards, personal protective equipment (PPEs) for vaccinators;
- (f) developing standards and protocols surrounding cold chain, supplies, storage, logistics, and providing related training; and
- (g) strengthening service delivery capacity, including *inter alia*: implementing national risk-communication and a community engagement plan for COVID-19, establishing strong post-vaccination vigilance and monitoring systems through the use of digital health technologies, including through the strengthening and adaptation of the Pharmacovigilance System (PVS).

Part 2: Project Implementation and Monitoring and Evaluation

Supporting the Project Coordination Unit for day to day implementation, coordination, supervision and overall management (including, fiduciary aspects, monitoring and evaluation, carrying out of audits and reporting) of Project activities.

SCHEDULE 2

Project Execution

Section I. Implementation Arrangements

A. Institutional Arrangements

1. Ministry of Finance

The Recipient, through the Ministry of Finance (“MoF”), shall be responsible for the prompt and efficient oversight and implementation of activities under the Project, and take all actions including the provision of funding, personnel and other resources necessary to perform said functions.

2. Project Coordination Unit

Without limitation upon the provisions of paragraph 1 of this Section I.A, the Recipient, through the MoF, shall designate, at all times during the implementation of the Project, the Project Coordination Unit (“PCU”), to be responsible for day to day execution, coordination and implementation (including procurement, financial management, environmental and social, monitoring and evaluation, supervision and reporting) of activities under the Project. To this end, the Recipient, through MOF, shall take all actions, including the provision of funding, personnel (including a Project coordinator, a procurement specialist, a financial management specialist, a financial management assistant, a procurement assistant, and an environmental and social development specialist), and other resources satisfactory to the Association, to enable the PCU to perform said functions, as further detailed in the Project Implementation Manual.

B. Implementation Arrangements

1. National COVID-19 Preparedness and Response Plan and National COVID-19 Immunization Plan

Without limitation to Section 3.01 of this Agreement, the Recipient shall ensure that the Project is carried out in accordance with the National COVID-19 Preparedness and Response Plan and the National COVID-19 Immunization Plan, all in a manner acceptable to the Association.

2. Project Implementation Manual

- (a) The Recipient shall, not later than thirty (30) days after the Effective Date, or such later date as agreed by the Association, update and adopt the Project Implementation Manual in a manner and on terms acceptable to the Association, containing, *inter alia*, detailed guidelines and procedures

for the implementation of the Project, including with respect to: (i) administration and coordination, monitoring and evaluation, financial management, procurement and accounting procedures, environmental and social safeguards, corruption and fraud mitigation measures, a grievance redress mechanism, personal data collection and processing in accordance with applicable national law and good international practice, roles and responsibilities for Project implementation, and such other arrangements and procedures as shall be required for the effective implementation of the Project, in form and substance satisfactory to the Association; (ii) rules and procedures for prioritizing intra-country vaccine allocation following principles established in the WHO Fair Allocation Framework, including an action plan setting out the timeline and steps for implementing such rules; (iii) rules and procedures establishing minimum standards for vaccine management and monitoring, including medical and technical criteria, communications and outreach plan, cold chain infrastructure, and other related logistics infrastructure; and (iv) vaccine distribution plan, including action plan setting out timeline and steps for immunization.

- (b) Except as the Association shall otherwise agree, the Recipient shall not assign, amend, abrogate, or waive the provisions of the Project Implementation Manual without prior approval of the Association.
- (c) In the event of any conflict between the provisions of the Project Implementation Manual and the provisions of this Agreement, the provisions of this Agreement shall prevail.

3. Work Plan and Budget

- (a) The Recipient shall: (a) not later than thirty (30) days after the Effective Date, or such later date as agreed by the Association, prepare and furnish to the Association, a work plan and budget (“Work Plan and Budget”), satisfactory to the Association, which shall include, *inter alia*, the activities to be carried out under the Project and a financing plan for expenditures required for such activities, setting forth the amounts and sources of financing; and (b) thereafter carry out said Work Plan and Budget in accordance with its terms and in a manner acceptable to the Association.
- (b) The Recipient shall not make or allow to be made any change to the approved Work Plan and Budget without prior approval in writing by the Association.

C. Standards for Project COVID-19 Vaccine Approval

All Project COVID-19 Vaccines shall satisfy the Vaccine Approval Criteria.

D. Use of Military and Security Actors

1. Without limitations to the provisions of Section E.2 of this Schedule and if during Project implementation, the Recipient decides to use its military or security forces, the Recipient shall: (a) prior to any involvement of its forces in the carrying out of Project activities, send a written notice to the Association (in accordance with Section 11.01(b) of the General Conditions) communicating such decision, including the name of the military or security unit; and (b) all activities carried out by said military or security unit under the Project shall be under the control of MHSS and shall be undertaken exclusively for the purposes related to the Project. All goods, services, Operating Costs, and Training financed by the Credit proceeds may be used by said military or security unit under the direction and control of MHSS and strictly in accordance with the Project Implementation Manual and other arrangements or protocols that the Association may require for carrying out these activities.
2. Except as the Association may otherwise agree, the Recipient shall ensure that the ownership of any assets generated, goods procured, and works constructed by the military or security unit referred to in paragraph 1 of this Section out of the Financing proceeds shall be transferred to, or shall vest, with MHSS or any equivalent or appropriate line ministry or agency agreed with the Association.

E. Environmental and Social Standards

1. The Recipient shall ensure that the Project is carried out in accordance with the Environmental and Social Standards, in a manner acceptable to the Association.
2. Without limitation upon paragraph 1 above, the Recipient shall ensure that the Project is implemented in accordance with the Environmental and Social Commitment Plan (“ESCP”), in a manner acceptable to the Association. To this end, the Recipient shall ensure that:
 - (a) the measures and actions specified in the ESCP are implemented with due diligence and efficiency, and provided in the ESCP;
 - (b) sufficient funds are available to cover the costs of implementing the ESCP;
 - (c) policies and procedures are maintained, and qualified and experienced staff in adequate numbers are retained to implement the ESCP, as provided in the ESCP; and
 - (d) the ESCP, or any provision thereof, is not amended, repealed, suspended or waived, except as the Association shall otherwise agree in writing, as specified in the ESCP, and ensure that the revised ESCP is disclosed promptly thereafter.

3. In case of any inconsistencies between the ESCP and the provisions of this Agreement, the provisions of this Agreement shall prevail.
4. The Recipient shall ensure that:
 - (a) all measures necessary are taken to collect, compile and furnish to the Association through regular reports, with the frequency specified in the ESCP, and promptly in a separate report or reports, if so requested by the Association, information on the status of compliance with the ESCP and the environmental and social instruments referred to therein, all such reports in form and substance acceptable to the Association, setting out, *inter alia*: (i) the status of implementation of the ESCP; (ii) conditions, if any, which interfere or threaten to interfere with the implementation of the ESCP; and (iii) corrective and preventive measures taken or required to be taken to address such conditions; and
 - (b) the Association is promptly notified of any incident or accident related to or having an impact on the Project which has, or is likely to have, a significant adverse effect on the environment, the affected communities, the public or workers, in accordance with the ESCP, the environmental and social instruments referenced therein and the Environmental and Social Standards.
5. The Recipient shall establish, publicize, maintain and operate an accessible grievance mechanism, to receive and facilitate resolution of concerns and grievances of Project-affected people, and take all measures necessary and appropriate to resolve, or facilitate the resolution of, such concerns and grievances, in a manner acceptable to the Association.

F. TPM Agency

For purposes of assisting the Recipient in the administration and deployment of Project COVID-19 Vaccines in accordance with the National COVID-19 Immunization Plan, the Recipient shall, not later than sixty (60) days after the Effective Date, or such later date as agreed by the Association, appoint a TPM Agency, with terms of reference, qualifications and experience satisfactory to the Association. To this end, the Recipient shall: (i) require the TPM Agency to prepare and submit monthly monitoring reports on vaccine administration and deployment, which shall be promptly made available to and discussed with the Association; and (ii) promptly take any actions, as may be requested by the Association upon its review of the TPM Agency's reports.

Section II. Project Monitoring, Reporting and Evaluation

The Recipient shall furnish to the Association each Project Report not later than forty-five (45) days after the end of each calendar semester, covering the calendar semester. Except as may otherwise be explicitly required or permitted under this Agreement or as may be explicitly requested by the Association, in sharing any information, report or document related to the activities described in Schedule 1 of this Agreement, the Recipient shall ensure that such information, report or document does not include Personal Data.

Section III. Withdrawal of the Proceeds of the Financing

A. General

Without limitation upon the provisions of Article II of the General Conditions and in accordance with the Disbursement and Financial Information Letter, the Recipient may withdraw the proceeds of the Financing to finance Eligible Expenditures in the amount allocated and, if applicable, up to the percentage set forth against each Category of the following table:

Category	Amount of the Credit Allocated (expressed in SDR)	Percentage of Expenditures to be Financed (inclusive of Taxes)
(1) Goods, non-consulting services and consulting services, Operating Costs and Training for the Project under Parts 1.2(a), 1.2(c), 1.2(e), 1.2(f), 1.2(g) and Part 2 of the Project	2,000,000	100%
(2) Acquisition, storage and distribution of Project COVID-19 Vaccines under Part 1.2(d) of the Project	5,000,000	100%
TOTAL AMOUNT	7,000,000	

B. Withdrawal Conditions; Withdrawal Period

1. Notwithstanding the provisions of Part A above, no withdrawal shall be made for payments made prior to the Signature Date, except that withdrawals up to an

aggregate amount not to exceed SDR 1,400,000 may be made for payments made prior to this date but on or after June 24, 2021, for Eligible Expenditures.

2. The Closing Date is December 31, 2022.

Section IV. Other Undertakings

The Recipient shall, not later than thirty (30) days after the Effective Date, or such later date as agreed by the Association: (a) customize the Project's accounting software, in form and substance satisfactory to the Association; and (b) sign an addendum to the Project auditor's contract, in form and substance satisfactory to the Association.

SCHEDULE 3

Repayment Schedule

Date Payment Due	Principal Amount of the Credit repayable (expressed as a percentage)*
On each June 15 and December 15:	
commencing December 15, 2031 to and including June 15, 2041	1%
commencing December 15, 2041 to and including June 15, 2061	2%

* The percentages represent the percentage of the principal amount of the Credit to be repaid, except as the Association may otherwise specify pursuant to Section 3.05(b) of the General Conditions.

APPENDIX

Section I. Definitions

1. “Anti-Corruption Guidelines” means, for purposes of paragraph 5 of the Appendix to the General Conditions, the “Guidelines on Preventing and Combating Fraud and Corruption in Projects Financed by IBRD Loans and IDA Credits and Grants”, dated October 15, 2006 and revised in January 2011 and as of July 1, 2016.
2. “Category” means a category set forth in the table in Section III.A of Schedule 2 to this Agreement.
3. “COVAX Facility” means the COVID-19 Vaccine Global Access Facility, a mechanism through which demand and resources are pooled to support the availability of, and equitable access to, COVID-19 vaccines for all economies, and which is coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO.
4. “COVID-19” means the coronavirus disease caused by the 2019 novel coronavirus (SARS-CoV-2).
5. “Environmental and Social Commitment Plan” or “ESCP” means the environmental and social commitment plan for the Project, dated March 25, 2020 and updated on June 23, 2021 as the same may be amended from time to time in accordance with the provisions thereof, which sets out the material measures and actions that the Recipient shall carry out or cause to be carried out to address the potential environmental and social risks and impacts of the Project, including the timeframes of the actions and measures, institutional, staffing, training, monitoring and reporting arrangements, and any environmental and social instruments to be prepared thereunder.
6. “Environmental and Social Management Framework” or “ESMF” means the environmental and social management framework to be prepared and adopted by the Recipient, and deemed satisfactory to the Association, setting out the principles, rules, guidelines and procedures to screen and assess the potential adverse environmental and social risks and impacts (including health and safety issues) of Project activities, including the risks of gender-based violence and sexual exploitation and abuse, adopt measures to avoid, reduce, mitigate or offset environmental and social adverse risks and impacts, including: the principles, organizational arrangements (including consultation, budget and disclosure); measures that endeavor to prevent and respond to gender-based violence, sexual exploitation and abuse, procedural, budget and institutional arrangements and actions needed to implement these measures, and information on the agency or agencies responsible for addressing the Project’s risks and impacts; as well as for

the preparation of any environmental and social instruments referred to therein, as such framework may be amended by the Recipient from time to time, with the prior written agreement of the Association.

7. “Environmental and Social Standards” or “ESSs” means, collectively: (i) “Environmental and Social Standard 1: Assessment and Management of Environmental and Social Risks and Impacts”; (ii) “Environmental and Social Standard 2: Labor and Working Conditions”; (iii) “Environmental and Social Standard 3: Resource Efficiency and Pollution Prevention and Management”; (iv) “Environmental and Social Standard 4: Community Health and Safety”; (v) “Environmental and Social Standard 5: Land Acquisition, Restrictions on Land Use and Involuntary Resettlement”; (vi) “Environmental and Social Standard 6: Biodiversity Conservation and Sustainable Management of Living Natural Resources”; (vii) “Environmental and Social Standard 7: Indigenous Peoples/Sub-Saharan Historically Underserved Traditional Local Communities”; (viii) “Environmental and Social Standard 8: Cultural Heritage”; (ix) “Environmental and Social Standard 9: Financial Intermediaries”; (x) “Environmental and Social Standard 10: Stakeholder Engagement and Information Disclosure”; effective on October 1, 2018, as published by the Association.
8. “GBV” means gender-based violence.
9. “GBV/SEA/SH Prevention and Response Action Plan” or “GBV Action Plan” means the action plan to be prepared and adopted by the Recipient, and deemed satisfactory to the Association, which outlines how the Project will put in place the necessary protocols and mechanisms to address the GBV/SEA/SH risks, and how to address any SEA/SH allegations that may arise, including specific arrangements for the Project by which SEA/SH risks will be addressed.
10. “General Conditions” means the “International Development Association General Conditions for IDA Financing, Investment Project Financing”, dated December 14, 2018 (revised on August 1, 2020 and April 1, 2021).
11. “Labor Management Procedures” or “LMP” means, the Labor Management Procedures to be prepared and adopted by the Recipient, and deemed satisfactory to the Association, identifying labor requirements and setting out the procedures for addressing labor conditions and risks associated with the Project activities, which is intended to help the Project identify the resources necessary to address Project labor issues. The LMP is enshrined within the context of the World Bank Environmental and Social Standards (ESS) 2: Labor and Working Conditions.
12. “Medical Waste Management Plan” or “MWMP” means the plan to be prepared and adopted by the Recipient, and deemed satisfactory to the Association, detailing existing systems in practice for waste management and provide the action plan to prevent and/or mitigate the negative effects of medical waste on human health and the environment.

13. “MHSS” means the Recipient’s ministry responsible for health, and any successor thereto.
14. “Ministry of Finance” or “MoF” means the Recipient’s ministry responsible for finance, and any successor thereto.
15. “MPA Program” means the global emergency multiphase programmatic approach program designed to assist countries to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness.
16. “National COVID-19 Immunization Plan” means the Recipient’s immunization plan for COVID-19, dated February 11, 2021, and acceptable to the Association, as said document may be modified from time to time, and such term includes all schedules and annexes to said document.
17. “National COVID-19 Preparedness and Response Plan” means the Recipient’s emergency preparedness and response plan for COVID-19, dated March 17, 2020, and acceptable to the Association, as said document may be modified from time to time, and such term includes all schedules and annexes to said document.
18. “Operating Costs” means the reasonable incremental expenses arising under the Project, and based on the Work Plan and Budget, on account of vehicle operation and maintenance, maintenance of equipment, communication and insurance costs, office administration costs, utilities, rentals, accommodation, banking charges, advertising expenses, travel and *per diem*, but excluding the salaries of the Recipient’s civil servants.
19. “Original Financing Agreement” means the financing agreement for the Cabo Verde COVID-19 Preparedness and Response Project between the Recipient and the Association, dated April 6, 2020 (Credit Number 6597-CV).
20. “Original Project” means the Cabo Verde COVID-19 Preparedness and Response Project financed through the Original Financing Agreement.
21. “Personal Data” means any information relating to an identified or identifiable individual. An identifiable individual is one who can be identified by reasonable means, directly or indirectly, by reference to an attribute or combination of attributes within the data, or combination of the data with other available information. Attributes that can be used to identify an identifiable individual include, but are not limited to, name, identification number, location data, online identifier, metadata and factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of an individual.

22. “Pharmacovigilance System” or “PVS” means a system used by an organization to fulfill its tasks and responsibilities about detecting, assessing, understanding, and preventing adverse effects or any other drug-related problem and detect any change to their risk-benefit balance.
23. “Procurement Regulations” means, for purposes of paragraph 85 of the Appendix to the General Conditions, the “World Bank Procurement Regulations for IPF Borrowers”, dated November 2020.
24. “Project Coordination Unit” means the Recipient’s unit referred to in Section I.A.2 of Schedule 2 to this Agreement.
25. “Project COVID-19 Vaccine” means a vaccine for the prevention of COVID-19, authorized by the Recipient’s national regulatory authority for distribution, marketing and administration within the territory of the Recipient, and acquired or deployed under the Project; “Project COVID-19 Vaccines” means the plural thereof.
26. “Project Implementation Manual” means the Recipient’s manual acceptable to the Association, and referred to in Section I.B.2 (a) of Schedule 2 to this Agreement, as such manual may be amended from time to time with the agreement of the Association.
27. “SEA” means sexual exploitation and abuse.
28. “SH” means sexual harassment.
29. “Stakeholder Engagement Plan” or “SEP” means the same plan prepared for the Original Project and to be updated, disclosed, consulted upon and adopted for the purpose of this Additional Financing.
30. “Signature Date” means the later of the two dates on which the Recipient and the Association signed this Agreement and such definition applies to all references to “the date of the Financing Agreement” in the General Conditions.
31. “Stringent Regulatory Authority” means a National Regulatory Authority (“NRA”) that is classified by WHO as a Stringent Regulatory Authority.
32. “TPM Agency” means the third-party monitoring agency referred to in Section I.F of Schedule 2 to this Agreement.
33. “Training” means expenditures for Project related study tours, training courses, seminars, workshops and other training activities not included under goods or service providers’ contracts, including costs of training materials, space and equipment rental, travel and *per diem* costs of trainees and trainers.

34. “Vaccine Approval Criteria” means that the Project COVID-19 Vaccine: (a) has received regular or emergency licensure or authorization from at least one of the Stringent Regulatory Authorities identified by WHO for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; (b) has received the WHO Prequalification or WHO Emergency Use Listing; or (c) has met such other criteria as may be agreed in writing between the Recipient and the Association.
35. “WHO” means the specialized agency of the United Nations established pursuant to the Constitution of the World Health Organization, dated July 22, 1946, as amended from time to time.
36. “WHO Emergency Use Listing” means a risk-based procedure for assessing and listing by WHO of unlicensed vaccines, therapeutics, and in vitro diagnostics with the aim of expediting the availability of these products to people affected by a declared public health emergency.
37. “WHO Fair Allocation Framework” means the rules which govern the allocation of vaccines to participants in the COVAX Facility, as developed by WHO, subject to periodic review by the COVAX Facility.
38. “WHO Prequalification” means a service provided by WHO to assess the quality, safety, and efficacy of medical products for priority diseases, and which are intended for United Nations and international procurement to developing countries.
39. “Work Plan and Budget” means the work plan and budget acceptable to the Association referred to in Section I.B.3 of Schedule 2 to this Agreement, as said work plan and budget may be modified from time to time with the written agreement of the Association.
40. “Workers GRM” means a grievance redress mechanism provided for all direct workers and contracted workers for the Project, aimed to raise workplace concerns, and provided separately from the Project-level grievance mechanism required under ESS10.

Section II. First Amendment to the Financing Agreement for COVID-19 Emergency Response Project Additional Financing on Vaccines (Credit Number 6837-CV) (“AF II”)

The Financing Agreement for AF II is amended as set forth in this Section II of the Appendix to this Agreement.

1. **Description of Project activities: Part 1.2(g) of Schedule 1 is amended to read as follows:**

“(g) strengthening service delivery capacity, including *inter alia*: implementing national risk-communication and a community engagement plan for COVID-19, establishing strong post-vaccination vigilance and monitoring systems through the use of digital health technologies, including through the strengthening and adaptation of the Pharmacovigilance System (PVS).”

2. **Third-Party Monitoring:** Section I of Schedule 2 is amended by inserting the following paragraph:

“F. TPM Agency

For purposes of assisting the Recipient in the administration and deployment of Project COVID-19 Vaccines in accordance with the National COVID-19 Immunization Plan, the Recipient shall, not later than sixty (60) days after the Effective Date, or such later date as agreed by the Association, appoint a TPM Agency, with terms of reference, qualifications and experience satisfactory to the Association. To this end, the Recipient shall: (i) require the TPM Agency to prepare and submit monthly monitoring reports on vaccine administration and deployment, which shall be promptly made available to and discussed with the Association; and (ii) promptly take any actions, as may be requested by the Association upon its review of the TPM Agency’s reports.”

3. **Closing Date:** Section III.B.2 of Schedule 2 is amended to read as follows:

“2. The Closing Date is December 31, 2022.

4. **Amendment to the Appendix definitions:** The definitions in the Appendix are amended by:

(a) inserting the following definitions:

““COVAX Facility” means the COVID-19 Vaccine Global Access Facility, a mechanism through which demand and resources are pooled to support the availability of, and equitable access to, COVID-19 vaccines for all economies, and which is coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO.”; and

““WHO Emergency Use Listing” means a risk-based procedure for assessing and listing by WHO of unlicensed vaccines, therapeutics, and in vitro diagnostics with the aim of expediting the availability of these products to people affected by a declared public health emergency.”

- (b) amending the definitions on “Project COVID-19 Vaccine”, “Vaccine Approval Criteria” and “WHO Fair Allocation Framework”, as follows:

““Project COVID-19 Vaccine” means a vaccine for the prevention of COVID-19, authorized by the Recipient’s national regulatory authority for distribution, marketing and administration within the territory of the Recipient, and acquired or deployed under the Project; “Project COVID-19 Vaccines” means the plural thereof.”;

““Vaccine Approval Criteria” means that the Project COVID-19 Vaccine: (a) has received regular or emergency licensure or authorization from at least one of the Stringent Regulatory Authorities identified by WHO for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; (b) has received the WHO Prequalification or WHO Emergency Use Listing; or (c) has met such other criteria as may be agreed in writing between the Recipient and the Association.”; and

““WHO Fair Allocation Framework” means the rules which govern the allocation of vaccines to participants in the COVAX Facility, as developed by WHO, subject to periodic review by the COVAX Facility.”